Commonwealth Equity Services LLC Boosts Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Commonwealth Equity Services LLC boosted its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 7.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 102,662 shares of the biotechnology company’s stock after purchasing an additional 7,285 shares during the period. Commonwealth Equity Services LLC’s holdings in Anavex Life Sciences were worth $1,103,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Orion Capital Management LLC raised its holdings in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 10,000 shares during the last quarter. PVG Asset Management Corp purchased a new stake in Anavex Life Sciences in the 3rd quarter valued at about $74,000. BNP Paribas Financial Markets boosted its position in shares of Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 7,421 shares during the period. Erste Asset Management GmbH purchased a new position in shares of Anavex Life Sciences during the third quarter worth $102,000. Finally, Berkshire Money Management Inc. acquired a new position in Anavex Life Sciences in the 4th quarter valued at about $107,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Trading Down 1.6 %

AVXL stock opened at $8.58 on Tuesday. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44. The company has a market cap of $729.85 million, a P/E ratio of -15.60 and a beta of 0.94. The company’s 50-day moving average price is $8.99 and its 200 day moving average price is $8.35.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, equities research analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AVXL shares. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research note on Monday.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.